ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study to Assess the Bioavailability of ASP015K

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ASP015K

First Posted Date: 2011-09-07

Last Posted Date: 2011-09-07

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 12

Registration Number: NCT01430078

Locations: 🇬🇧
Quotient Clinical Limited, Ruddington, Nottingham, United Kingdom

A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics of ASP0456

Interventions: Drug: Placebo
Drug: ASP0456

First Posted Date: 2011-09-01

Last Posted Date: 2011-09-23

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 44

Registration Number: NCT01427387

To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects

Phase 1

Completed

Conditions: Pharmacodynamic and Pharmacokinetic Interaction
Healthy Subjects

Interventions: Drug: Darexaban
Drug: Acetyl Salicylic Acid (ASA)

First Posted Date: 2011-08-29

Last Posted Date: 2011-08-29

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT01424332

Locations: 🇫🇷
SGS Aster, Paris, France

Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males

Phase 1

Completed

Conditions: Healthy Adult Male
Pharmacokinetics of TRK-100-STP

Interventions: Drug: TRK-100STP

First Posted Date: 2011-08-26

Last Posted Date: 2011-10-04

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 36

Registration Number: NCT01423435

Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch

Phase 4

Completed

Conditions: or Peripheral Nerve Injury (PNI)
Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)

Interventions: Drug: QUTENZA
Drug: Tramadol
Drug: Lidocaine

First Posted Date: 2011-08-12

Last Posted Date: 2018-04-23

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 122

Registration Number: NCT01416116

Locations: 🇧🇪
Site 102, Antwerpen, Belgium
🇧🇪
Site 103, Genk, Belgium
🇧🇪
Site 101, Roeselare, Belgium

and more 17 locations

A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Tacrolimus

First Posted Date: 2011-08-05

Last Posted Date: 2024-10-22

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1484

Registration Number: NCT01410747

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Phase 1

Completed

Conditions: Medical Oncology
Neoplasms
Tumors

Interventions: Drug: AGS-22M6E
Drug: ASG-22CE

First Posted Date: 2011-08-04

Last Posted Date: 2024-03-12

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 34

Registration Number: NCT01409135

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Colorado, Denver-Aurora, Aurora, Colorado, United States

and more 6 locations

To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects

Phase 1

Completed

Conditions: Pharmacodynamic Interaction
Healthy Subjects

Interventions: Drug: darexaban
Drug: Naproxen

First Posted Date: 2011-08-04

Last Posted Date: 2013-04-11

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 26

Registration Number: NCT01409603

Locations: 🇫🇷
SGS Aster, Paris, France

To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects

Phase 1

Completed

Conditions: Pharmacodynamic Interaction
Healthy Subjects

Interventions: Drug: darexaban
Drug: darexaban (double dose)
Drug: Acetyl Salicylic Acid
Drug: clopidogrel

First Posted Date: 2011-08-04

Last Posted Date: 2013-03-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 100

Registration Number: NCT01409616

Locations: 🇫🇷
SGS Aster, Paris, France

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

Phase 1

Completed

Conditions: Pharmacokinetics of Solifenacin Succinate
Healthy Volunteers

Interventions: Drug: Solifenacin Succinate Formulation B
Drug: Solifenacin Succinate Formulation A
Drug: Solifenacin Succinate

First Posted Date: 2011-08-01

Last Posted Date: 2011-08-24

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT01406158

Locations: 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy